Evidence map›Paper›PMID 33609235›Full record

ArticleArchives of pharmacal research2021

MiR-340 regulates the growth and metabolism of renal cell carcinoma cells by targeting frizzled class receptor 3.

Mingfeng Xiang, Yanqun Huang, Changjun Dai, Gaode Zou

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of pharmacal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mingfeng XiangDepartment of Urology, The Second Affiliated Hospital of Nanchang University, 1 Mingde RD, Nanchang, 310003, China.
Yanqun HuangSchool of Inter-Cultural Studies, Jiangxi Normal University, Nanchang, 330022, China.
Changjun DaiPeople's Hospital of Linchuan District, Fuzhou City, 344000, Jiangxi Province, China.
Gaode ZouDepartment of Urology, The Second Affiliated Hospital of Nanchang University, 1 Mingde RD, Nanchang, 310003, China. Gaode_zou@163.com.
Second Affiliated Hospital of Nanchang University · CNJiangxi Normal University · CN

Funding

This study was supported by Grants from the Natural Science Foundation of Jiangxi Province, China: Identification of Metabolic Markers in Renal Tumor and Research on Its Diagnostic Prediction Model. 20181BAB205055
6 · The paper itself

Abstract

MicroRNA(miR)-340 is known as a multifunctional miRNA related to various types of cancer while its role in renal cell carcinoma (RCC) remains to be further investigated. In the present study, an apparent increase in miR-340 expression was observed in both clear cell RCC tissues and RCC cell line 786-O and Caki-1. Functionally, the overexpression of miR-340 promoted cell proliferation, migration, invasion, extracellular alanine (Ala) level, and glycolysis level in 786-O cells. Then, frizzled class receptor 3 (FZD3) was determined as the target gene of miR-340 and its expression level was negatively regulated by miR-340. The FZD3 silencing abrogated the inhibitory effect of miR-340 knockdown on cell proliferation, migration, invasion, Ala level, and glycolysis level in 786-O cells. In conclusion, miR-340 promotes proliferation, migration, and invasion of RCC cells via suppressing FZD3 expression, and the promotion effect of miR-340 on RCC progression may be due to its regulatory effect on glycolysis and Ala level.

Indexed as

Carcinoma, Renal CellCell Line, TumorCell ProliferationFrizzled ReceptorsHumansKidney NeoplasmsMicroRNAsFrizzled ReceptorsFZD3 protein, humanMicroRNAsMIRN340 microRNA, humanAlanineFrizzled class receptor 3GlycolysismiR-340Renal cell carcinoma

Identifiers

PMID33609235
OpenAlexW3130691094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.